 MELBOURNE, Australia, July 15, 2021 PRNewswire -- Alterity Therapeutics ASX: ATH, NASDAQ: ATHE Alterity or the Company, a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced that Movement Disorders, the official journal of the International Parkinson and Movement Disorder Society, has published results from a study demonstrating that ATH434 reduces αsynuclein related neurodegeneration in a widely accepted murine model of Multiple System Atrophy MSA1. The publication of data demonstrating that ATH434 preserves neurons while reducing αsynuclein in areas of pathology is exactly what we were hoping to see as we advance to clinical trials in MSA, said Alterity Chief Executive Officer David Stamler, M.D. 